Immunocompromised status due to: xHuman immunodeficiency virus (HIV) positivity. Version Date: 12/5/17 Abbreviated Title : Enzalutamide in non-met CSPC 25xActive autoimmune diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave's disease. Patients with a history of autoimmuni ty that has not required systemic immunosuppressive therapy or does not threaten vital organ function including CNS, heart, lungs, kidneys, skin, and GI tract will be allowed. xOther immunodeficiency diseases B. Chronic administration (defined as dail y or every other day for continued use > 14 days) of corticosteroids deemed systemic by investigator within 28 days before the first planned dose of PSA-TRI COM. Use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed. C. Serious intercurrent medical illness that, in the judgment of the investigator, would interfere with patient’s ability to carry out the treatment program. D. History of seizure, including any febr ile seizure, loss of consciousness, or transient ischemic attack, or any cond ition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous ma lformation, head trauma with loss of consciousness requiring hospitalization). E. Other medications used for urinary symptoms including 5-alpha reductase inhibitors (finasteride an d dutasteride) and alterna tive medications known to alter PSA (eg phytoestro gens and saw palmetto) F. History of prior chemotherapy G.